PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib

This study has been completed.
Sponsor:
Collaborator:
Bayer
Information provided by:
Helsinki University
ClinicalTrials.gov Identifier:
NCT00117299
First received: June 30, 2005
Last updated: May 25, 2010
Last verified: May 2010
  Purpose

This study evaluates the safety and efficacy of a novel tyrosine kinase inhibitor, PTK787/ZK222584, in the treatment of GIST (gastrointestinal stromal tumor) that is resistant to imatinib mesylate (Gleevec). The study participants are required to have histologically confirmed GIST with prior imatinib treatment for metastatic GIST. is administered orally 1250 mg/day. Six patients will first enter the study. If clinical benefit is obtained in >1 of 6 patients, 9 and 30 additional patients will be entered into the protocol in two stages (a maximum of 45 patients will be entered). Patients who benefit from the study treatment will be treated with PTK787/ZK222584 until treatment failure.


Condition Intervention Phase
Sarcoma
Drug: PTK787/ZK222584
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Open-Label Study of PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors (GISTs) Resistant to Imatinib Mesylate

Resource links provided by NLM:


Further study details as provided by Helsinki University:

Primary Outcome Measures:
  • Response rate [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 45
Study Start Date: September 2004
Study Completion Date: January 2009
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
PTK/ZK o.d. 1250 mg p.o.
Drug: PTK787/ZK222584
PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally
Other Name: vatalanib

Detailed Description:

This is an open-label, phase II study of PTK787/ZK222584 designed to determine the safety and efficacy of PTK787/ZK222584 in the treatment of imatinib-resistant GIST. The PTK787/ZK222584 dose used is 1250 mg daily. Six patients will first enter the study using a two-stage approach. If clinical benefit is obtained in >1 of 6 patients, 9 and 30 additional patients will be entered into the protocol (a maximum total number of 45 patients will be entered). Clinical benefit is defined as the occurrence of one or more of the following 3 measures: 1) objective response to PTK787 (a confirmed or unconfirmed partial response [PR] or a complete response [CR]); 2) metabolic response defined as >50% decrease in the standardized uptake value (SUV) of FDG uptake in >1 FDG-avid lesions in one or more of the patients; or 3) stabilized disease for 3 months or longer accompanied by symptomatic or performance status improvement. Medical history, current medical conditions, weight, height, and an electrocardiogram are recorded prior to the study entry. Other baseline examinations include a chest X-ray, hematologic tests, a coagulation panel, serum chemistries, urine analysis, a serum pregnancy test and a radiological assessment of the tumor. Tumor response is monitored with imaging at 4- to 8-week intervals. Hematological tests and serum chemistries are evaluated at 1- to 4-week intervals, and adverse events are collected continuously. Research blood tests are collected at the times of tumor evaluations. Dose adjustments are carried out as per the protocol. Patients who benefit from the study treatment will be treated with PTK787/ZK222584 until treatment failure.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histologically confirmed GIST
  • Imatinib resistance (primary resistance with progression, or progression after initial response). Resistance is defined as objective evidence of progression after at least 4 weeks of treatment with imatinib.
  • Imatinib therapy has been interrupted >7 days before study entry
  • Metastatic disease confirmed histologically, cytologically or radiologically
  • Presence of measurable tumor lesions as determined by RECIST criteria
  • Age 18 years or older
  • WHO performance status of 2 or less
  • Blood neutrophil count (ANC) 1.5 x 10^9/L or higher
  • Platelet count 100 x 10^9/L or higher
  • Serum bilirubin 1.5 x ULN (upper limit of normal) or less
  • Serum creatinine 2.0 x ULN or less
  • Written informed consent obtained according to local guidelines

Exclusion Criteria:

  • Patients who have received chemotherapy less than 4 weeks prior to entry into this study or who have not recovered from side effects of such therapy
  • Patients who have received a cumulative dose of doxorubicin >450 mg/m2 or epirubicin 800 mg/m2
  • Patients who have received immunotherapy within 2 weeks or who have not recovered from side effects of such therapy
  • Patients who have received radiotherapy within 2 weeks or who have not recovered from side effects of such therapy
  • Major surgery within 2 weeks prior to entry into this study or patients who have not recovered from side effects of such therapy
  • Patients who have received investigational drugs within 4 weeks prior to entry into this study or who have not recovered from side effects of such therapy
  • Patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control
  • Concurrent severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, congestive cardiac failure, myocardial infarction within 6 months, poorly controlled hypertension, history of labile hypertension, history of poor compliance with antihypertensive regimen, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study
  • Acute or chronic liver disease (e.g., hepatitis, cirrhosis)
  • Confirmed diagnosis of HIV infection
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of PTK787/ZK222584 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, bowel obstruction, or inability to swallow the capsules/tablets)
  • Patients who are taking Coumadin (warfarin sodium); heparin is acceptable.
  • Patients unwilling to, or unable to, comply with the protocol
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00117299

Locations
Finland
Helsinki University Central Hospital
Helsinki, Finland, FIN-00029
Sponsors and Collaborators
Helsinki University
Bayer
Investigators
Principal Investigator: Heikki Joensuu, M.D. Department of Oncology, Helsinki University Central Hospital
  More Information

No publications provided

Responsible Party: Heikki Joensuu, Helsinki University central Hospital
ClinicalTrials.gov Identifier: NCT00117299     History of Changes
Other Study ID Numbers: CPTK787 A2401/300267, GIST PTK787/ZK222584
Study First Received: June 30, 2005
Last Updated: May 25, 2010
Health Authority: Finland: Finnish Medicines Agency

Keywords provided by Helsinki University:
Gastrointestinal stromal tumor
GIST
Sarcoma
PTK787
ZK 222584
Tyrosine kinase inhibitor
Tyrosine kinase
VEGF
Vascular endothelial growth factor
VEGFR
Vascular endothelial growth factor receptor
KDR
KIT
c-KIT
Platelet derived growth factor receptor
PDGFR

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Sarcoma
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Endothelial Growth Factors
Imatinib
Vatalanib
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 17, 2014